ArticleJCI insight2017
Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial.
Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02283242 (Effects of Cholinergic Stimulation on Visceral Fat, Oxidative Stress and Inflammatory Markers in Patients With Metabolic Syndrome), which is not on this map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Cholinergic Stimulation on Visceral Fat, Oxidative Stress and Inflammatory Markers in Patients With Metabolic Syndrome: a Randomized Clinical Trial
Who cites it
54 citing papers in PubMed, 90 citations in OpenAlex.
- Effect of transcutaneous auricular vagus nerve stimulation on delayed neurocognitive recovery in elderly patients.Aging clinical and experimental research · 2022Trial
- The Cholinergic Drug Galantamine Alleviates Oxidative Stress Alongside Anti-inflammatory and Cardio-Metabolic Effects in Subjects With the Metabolic Syndrome in a Randomized Trial.Frontiers in immunology · 2021Trial
- Acetylcholinesterase inhibitor therapy mitigates hypertension in lupus mice.Clinical science (London, England : 1979) · 2026Article
- Neuroimmune Dynamics in Diseases of the Arterial Wall: Mechanistic Foundations and Translational Prospects.Current atherosclerosis reports · 2026Review
- Role of central and peripheral serotonin in liver physiology and diseases.Theranostics · 2026Review
- Mendelian Randomization in Conjunction with WGCNA Was Employed to Investigate the Potential Role of the Liver-Brain Axis in the Pathogenesis of Hepatocellular Carcinoma and Alzheimer's Disease.Molecular neurobiology · 2025Article
- The cholinergic drug galantamine ameliorates acute and subacute peripheral and brain manifestations of acute respiratory distress syndrome in mice.Scientific reports · 2025Article
- Potential Impact of Choline Alphoscerate on Depressive Symptoms in Association with Insulin Resistance in Elderly Patients with Type 2 Diabetes.Journal of clinical medicine · 2025Article
- Donepezil improves skeletal muscle insulin resistance in obese mice via the AMPK/FGF21-mediated suppression of inflammation and ferroptosis.Archives of pharmacal research · 2024Article
- Autonomic function and change in functional capacity in older adults: a longitudinal investigation.Scientific reports · 2024Article
- Bridging cholinergic signalling and inflammation in schizophrenia.Schizophrenia (Heidelberg, Germany) · 2024Article
- Alzheimer Disease Treatment With Acetylcholinesterase Inhibitors and Incident Age-Related Macular Degeneration.JAMA ophthalmology · 2024Observational
- Galantamine ameliorates experimental pancreatitis.Molecular medicine (Cambridge, Mass.) · 2023Article
- Galantamine improves glycemic control and diabetic nephropathy in LeprScientific reports · 2023Article
- Serum cholinesterase is associated with incident diabetic retinopathy: the Shanghai Nicheng cohort study.Nutrition & metabolism · 2023Article
- Neuroimmune nexus in the pathophysiology and therapy of inflammatory disorders: Role of α7 nicotinic acetylcholine receptors.Pharmacological research · 2023Review
- Brief periods of transcutaneous auricular vagus nerve stimulation improve autonomic balance and alter circulating monocytes and endothelial cells in patients with metabolic syndrome: a pilot study.Bioelectronic medicine · 2023Article
- Association between initial in-hospital heart rate and glycemic control in patients with acute ischemic stroke and diabetes mellitus.BMC endocrine disorders · 2023Article
- Peripheral and central macrophages in obesity.Frontiers in endocrinology · 2023Review
- Galantamine attenuates autoinflammation in a mouse model of familial mediterranean fever.Molecular medicine (Cambridge, Mass.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 5 countries.
Funding
Abstract
backgroundMetabolic syndrome (MetS) is an obesity-driven condition of pandemic proportions that increases the risk of type 2 diabetes and cardiovascular disease. Pathophysiological mechanisms are poorly understood, though inflammation has been implicated in MetS pathogenesis. The aim of this study was to assess the effects of galantamine, a centrally acting acetylcholinesterase inhibitor with antiinflammatory properties, on markers of inflammation implicated in insulin resistance and cardiovascular risk, and other metabolic and cardiovascular indices in subjects with MetS.
methodsIn this randomized, double-blind, placebo-controlled trial, subjects with MetS (30 per group) received oral galantamine 8 mg daily for 4 weeks, followed by 16 mg daily for 8 weeks or placebo. The primary outcome was inflammation assessed through plasma levels of cytokines and adipokines associated with MetS. Secondary endpoints included body weight, fat tissue depots, plasma glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), cholesterol (total, HDL, LDL), triglycerides, BP, heart rate, and heart rate variability (HRV).
resultsGalantamine resulted in lower plasma levels of proinflammatory molecules TNF (-2.57 pg/ml [95% CI -4.96 to -0.19]; P = 0.035) and leptin (-12.02 ng/ml [95% CI -17.71 to -6.33]; P < 0.0001), and higher levels of the antiinflammatory molecules adiponectin (2.71 μg/ml [95% CI 1.93 to 3.49]; P < 0.0001) and IL-10 (1.32 pg/ml, [95% CI 0.29 to 2.38]; P = 0.002) as compared with placebo. Galantamine also significantly lowered plasma insulin and HOMA-IR values, and altered HRV.
conclusionLow-dose galantamine alleviates inflammation and insulin resistance in MetS subjects. These findings support further study of galantamine in MetS therapy.
trial registrationClinicalTrials.gov, number NCT02283242.
fundingFundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil, and the NIH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.